P3, N=90, Not yet recruiting, Nanjing Medical University

RTA-408 exerts antitumour and radiosensitizing effects via activation of the JNK pathway and inhibits GBM progression. These findings highlight its potential as a novel therapeutic strategy for the treatment of GBM.

P=N/A, N=100, Not yet recruiting, TC Erciyes University | Trial completion date: Jan 2027 --> Jun 2027 | Initiation date: Mar 2025 --> Nov 2025 | Trial primary completion date: Jan 2027 --> Jun 2027

Histone deacetylase inhibitors, such as vorinostat, show promise as treatment for T-cell lymphomas including cutaneous T-cell lymphoma...Histone deacetylase inhibitor-resistant cell lines displayed heightened sensitivity to inhibition of the NF-κB pathway by bortezomib and dimethyl fumarate. These findings implicate aberrant NF-κB activation as a central driver of the emergence of histone deacetylase inhibitor resistance in cutaneous T-cell lymphoma. Ultimately, our results provide a strong rationale for exploring NF-κB inhibition as a therapeutic strategy to restore or enhance the efficacy of histone deacetylase inhibitor-based therapies, overcome histone deacetylase inhibitor resistance, and improve outcomes for patients with cutaneous T-cell lymphoma.

Five groups of rats were randomly selected: vehicle-treated rats, DMF-treated rats, CIA-controlled rats, normal control rats, and methotrexate (MTX)-treated rats...The immunoregulatory activity of DMF may have contributed to its amelioration of RA. DMF might be studied as a possible new medicinal agent for the treatment of RA.

P=N/A, N=200, Not yet recruiting, Xuanwu Hospital Capital Medical University; Xuanwu Hospital Capital Medical University

P1, N=72, Completed, Merry Life Biomedical Co., Ltd. | Recruiting --> Completed | Trial primary completion date: Apr 2025 --> Jul 2025

P3, N=136, Completed, Biogen | N=102 --> 136

P1, N=22, Completed, Biogen | Recruiting --> Completed

DMF reduced the mitochondrial membrane potential and oxidative phosphorylation (OXPHOS), effects that were almost fully restored by the antioxidant N-acetylcysteine, suggesting that these responses are ROS-dependent...This combination also caused greater mitochondrial depolarization and a more profound reduction in OXPHOS activity than either agent alone. Collectively, our findings indicate that DMF exerts potent anti-leukemia activity in AML cells and sensitizes cells to venetoclax treatment by synergistically disrupting mitochondrial integrity through ROS accumulation.

This work elucidated that DMF reprograms CC cells to activate the mtDNA-cGAS-STING pathway, fostering a chemokine-rich microenvironment that recruits CD8+ T cells. The synergistic effect of DMF and PD-1 blockade or TIL therapy underscores its potential as an immunostimulatory adjuvant. These findings suggest that DMF holds promise as a novel immunotherapeutic strategy for improving clinical outcomes in CC.

P1, N=20, Recruiting, University of Nebraska | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026